Officer sold
24K → 23K shares held−3% of their stake
Incyte's Principal Accounting Officer sold $59K of Incyte shares. Nobody planned it ahead of time.
Loading…
Traded Dec 1, 2025 · Filed Dec 3, 2025
Incyte's & Chief Medical Officer sold $263K of Incyte shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$263,475
Shares × reported transaction price
34 days after results of Oct 28, 2025, 71 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $102.04 on Dec 1, 2025, 85% above its 52-week low and 6% below its high, after a 17% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 88% of the way up, from 250 adjusted closes. 30 trading days earlier: $87.57 on Oct 17, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 16 days after this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -4.3% | +0.7% | -5.0% |
| 30 days | +1.3% | +0.5% | +0.8% |
| 90 days | -1.6% | +0.1% | -1.7% |
| 180 days | -8.2% | +11.0% | -19.2% |
Past results only. Not a forecast.
24K → 23K shares held−3% of their stake
Incyte's Principal Accounting Officer sold $59K of Incyte shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
